Cargando…
Ribavirin aerosol in hospitalized adults with respiratory distress and COVID‐19: An open‐label trial
There is an unmet medical need for effective treatments for hospitalized patients with coronavirus disease 2019 (COVID‐19). Ribavirin is a broad‐spectrum antiviral with demonstrated in vitro activity against multiple viruses, including severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2). Th...
Autores principales: | Poulakou, Garyfallia, Barakat, Maxime, Israel, Robert J., Bacci, Marcelo R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9841304/ https://www.ncbi.nlm.nih.gov/pubmed/36326174 http://dx.doi.org/10.1111/cts.13436 |
Ejemplares similares
-
Ribavirin Aerosol in the Treatment of SARS-CoV-2: A Case Series
por: Messina, Emanuela, et al.
Publicado: (2021) -
A randomized, placebo‐controlled study to evaluate safety and pharmacokinetics of inhaled ribavirin
por: Couroux, Peter, et al.
Publicado: (2022) -
PEG interferon-α-2b/ribavirin: Interstitial pneumonitis and adult respiratory distress syndrome: case report
Publicado: (2013) -
Aerosolized Surfactant for Preterm Infants with Respiratory Distress Syndrome
por: Brasher, Mandy, et al.
Publicado: (2021) -
2640. Aerosol vs. Oral Ribavirin for the Treatment of Community-Acquired Respiratory Virus Infections in Lung Transplant Recipients
por: Mui, Emily, et al.
Publicado: (2019)